Furthermore, we determined the translational importance of this proposal in a clinical setting by showing that loss of MTSS1 and SCAMP1 expression are specifically associated with a worse prognosis in HER2+/ER−/PR− breast cancer. This evidence concerns the gene MTSS1 and breast cancer.